Inflammatory cytokines, growth factors, and depression

Current Pharmaceutical Design

Volumn 18, Issue 32, 2012, Pages 5920-5935

  Lotrich, Francis ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Brain derived neurotrophic factor; Inflammation; Interferon; Interleukin; Major depressive disorder

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; GROWTH FACTOR;

BLOOD BRAIN BARRIER; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; COGNITION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENETIC POLYMORPHISM; HUMAN; MAJOR DEPRESSION; MENTAL STRESS; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG TARGETING; INFLAMMATION; NEUROCHEMISTRY; SECOND MESSENGER;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; DRUG DESIGN; HUMANS; INFLAMMATION MEDIATORS; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION;

EID: 84867670386     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803523680     Document Type: Review

References (416)

1. Insel TR, Charney DS. Research on Major Depression Strategies and Priorities. JAMA 2003; 289: 3167-8.
2. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nature Medicine 1998; 4: 1241-3.
3. Panzarino PJJ. The costs of depression: direct and indirect; treatment versus nontreatment. J Clinical Psychiatry 1998; 59: 1-141.
4. Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009; 3: CD007954.
5. Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and effectiveness of antidepressants: current status of research. Psychotherapy Psychosomatics 2010; 79: 267-79.
6. Silverstein B, Patel P. Poor response to antidepressant medication of patients with depression accompanied by somatic symptomatology in the STAR*D Study. Psychiatry Res 2011; 187: 121-4.
7. Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Canadian J Psychiatry 2010; 55: 126-35.
8. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos G. The pathophysiologic roles of interleukin-6 in human disease. Annals of Internal Med 1998; 128: 127-37.
9. Wallace DJ, Linker-Israeli M, Hallegua D, et al. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatol 2001; 40: 743-9.
10. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behavior Immunol 2001; 15: 7-24.
11. Koo JW, Duman RS. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Current Opinion in Investigational Drugs 2009; 10: 664-71.
12. Franzen PL, Buysse DJ, Rabinovitz M, Pollock BG, Lotrich FE. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. J Psychiatric Res 2009; 177: 240-5.
13. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biological Psychiatry 2009; 65: 344-8.
14. Lotrich FE, Rabinovitz F, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosomatic Res 2007; 63: 131-5.
15. Sarder M, Abe K, Saito H, Nishiyama N. Comparative effect of IL-2 and IL-6 on morphology of cultured hippocampal neurons from fetal rat brain. Brain Res 1996; 715: 9-16.
16. Villeda SA, Luo J, Mosher JI, et al. The aging systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011; 477: 90-6.
17. Prossin AR, Koch AE, Campbell PL, et al. Association of plasma interleukin-18 levels with emotion regulation and mu-opioid neurotransmitter function in major depression and healthy volunteers. Biological Psychiatry 2011; 69: 808-12.
18. Lotrich FE, Loftis JM, Ferrell RE, Rabinovitz M, Hauser P. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interferon and Cytokine Res 2011; Epub ahead of print: doi:10.1089/jir.2010.0074
19. Saija A, Princi P, Lanza M, et al. Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sciences 1995; 56: 775-84.
20. Esposito P, Gheorghe D, Kandere K, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001; 888: 117-27.
21. Rivest S. How circulating cytokines trigger the neural circuits that control the hypothalamic-iptuitary-adrenal axis. Psychoneuroendocrinology 2001; 26: 761-88.
22. Rivest S, Lacroix S, Vallieres L, et al. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proceedings Soc Exp Biological Med 2000; 223: 22-38.
23. Konsman JP, Kelly K, Dantzer R. Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1beta mRNA and inducible nitric oxide synthase in rat brain. Neuroscience 1999; 89: 535-48.
24. Banks WA, Farr SA, Scola ME, Morley JE. Intravenous human interleukin-1a impairs memory processing in mice: dependence on blood-brain barrier transport into posterior division of the septum. J Pharmacol Exp Therapeut 2001; 299: 536-41.
25. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995; 2: 241-8.
26. Licinio J, Wong M-L. Pathways and mechanisms for cytokine signaling of the central nervous system. J Clinical Investigation 1997; 100: 2941-7.
27. Denicoff KD, Rubinow DR, Papa MA. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Internal Med 1987; 107: 293-300.
28. Raison CL, Borisov AS, Majer M, et al. Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression. Biological Psychiatry 2009; 65: 296-303.
29. Patel HC, Boutin H, Allan SM. Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Annals NY Academy Sci 2003; 992: 39-47.
30. Nguyen KT, Deak T, Owens SM, et al. Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci 1998; 18: 2739-46.
31. Zhu YS, Saito K, Murakami Y, et al. Early increase in mRNA levels of pro-inflammatory cytokines and their interactions in the mouse hippocampus after transient global ischemia. Neurosci Letters 2006; 393: 122-6.
32. Miyahara S, Komori T, Fujiwara R, et al. Effects of repeated stress on expression of IL-6 and IL-6 receptor mRNAs in rat hypothalamus and midbrain. Life Sci 2000; 66: PL93-PL8.
33. Nadeau S, Rivest S. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience 1999; 93: 1449-64.
34. Licinio J, Frost P. The neuroimmune-endocrine axis: pathophysiological implications for the central nervous system cytokines and hypothalamus-pituitary-adrenal hormone dynamics. Brazilian J Med Biological Res 2000; 33: 1141-8.
35. Peng CH, Chiou SH, Chen SJ, et al. Neuroprotection by imipramine against lipopolysaccharide-induced apoptosis in hippocampus-dreived neural stem cellsmediated by activation of BDNF and the MAPK pathway. Eur Neuropsychopharmacol 2008; 18: 128-40.
36. Katafuchi T, Kondo T, Yasaka T, et al. Prolonged effects of polyriboinosinic:polyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue. Neuroscience 2003; 120: 837-45.
37. Utsuyama M, Hirokawa K. Differential expression of various cytokine receptors in the brain after stimulation with LPS in young and old mice. Experimental Gerontol 2002; 37: 411-20.
38. Conti C, Park LCH, Calingasan NV, et al. Cultures of astrocytes and microglia express interleukin-18. Molecular Brain Res 1999; 67: 46-52.
39. Hansen MK, Taishi P, Chen Z, Krueger JM. Vagotomy blocks the induction of interleukin-1b (IL-1b) mRNA in the brain of rats in response to systemic IL-1b. J Neurosci 1998; 18: 2247-53.
40. Hosoi T, Okuma Y, Nomura Y. Electrical stimulation of afferent vagus nerve induces IL-1b expression in the brain and activatesHPA axis. Am J Physiol Regulatory Integrative Comparative Physiol 2000; 279: R141-R7.
41. Ljungdahl A, Olsson T, Vander Meide PH, et al. Interferongamma-like immunoreactivity in cerain neurons of the central and peripheral nervous system. J Neurosci Res 1989; 24: 451-6.
42. Janicki PK. Binding of human alpha-interferon in the brain tissue membranes of rat. Res Communications Chem Pathol Pharmicol 1992; 75: 117-20.
43. Yamada T, Yamanaka I. Microglial localization of alpha-interferon receptor in human brain tissues. Neuroscience Letters 1995; 189: 73-6.
44. Kiefer R, Kreutzbert GW. Gamma interferon-like immunoreactivity in the rat nervous system. Neuroscience 1990; 37: 725-34.
45. Parnet P, Amindari S, Wu C, et al. Expression of type I and type II interleukin-1 receptors in mouse brain. Molecular Brain Res 1994; 27: 63-70.
46. Ringheim GE, Burgher KL, Heroux JA. Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brain. J Neuroimmunol 1995; 63: 113-23.
47. Shizuya K, Komori T, Fujiwara R, et al. The expression of mRNAs for interleukin-6 (IL-6) and the IL-6 recptor (IL-6R) in the rat hypothalamus and midbrain during restraint stress. Life Sciences 1998; 62: 2315-20.
48. Twarog BM. Serotonin: history of a discovery. Comparative Biochemistry and Physiology 1988; 91C: 21-4.
49. Vgontzas AN, Bixler EO, Lin HM, et al. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 2005; 12: 131-40.
50. Kluger MJ. Fever: Role of pyrogens and cryogens. Physiol Rev 1991; 71: 93-127.
51. Mayer P, Geissler K, Valent P, et al. Recombinant human interleukin-6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. Experimental Hematol 1991; 19: 688-96.
52. Fisman EZ, Tenenbaum A. The ubiquitous interleukin-6: a time for reappraisal. Cardiovascular Diabetology 2010; 9: 62.
53. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brainderived neurotrophic factor. Brain Injury 2002; 125: 2381-91.
54. Wang CX, Shuaib A. Involvement of inflammatory cytokines in central nervous system injury. Progress Neurobiol 2002; 67: 161-72.
55. Larson SJ. Behavioral and motivational effects of immune-system activation. The J General Psychology 2002; 129: 401-14.
56. Hart BL. Behavioral adaptations to pathogens and parasites: Five strategies. Neuroscience and Biobehavioral Reviews 1990; 14: 273-94.
57. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002; 25: 154-9.
58. Miller NE. Some psychophysiological studies of motivation and of the behavioral effects of illness. Bulletin Br Psychological Soc 1964; 17: 1-20.
59. Avitsur R, Yirmiya R. The immunobiology of sexual behavior: gender differences in the suppression of sexual activity during illness. Pharmacology, Biochem Behavior 1999; 64: 787-96.
60. Goodall J. The Chimpanzees of Gombe: Patterns of Behavior, Belknap Press: Cambridge 1986.
61. Korda P. Epimeletic (care-giving) vomiting in dogs: A study of the determinating factors. Acta Neurobiologiae Experimentalis 1974; 34: 277-300.
62. Scott JP. Genetic analysis of social behavior, In Uniting psychology and biology: Integrative perspectives on human development, NL Segal, GE Weisfeld, CC Weisfeld, eds.; APA press: Washington DC, 1997, pp. 131-44.
63. Caldwell MC, Caldwell DK. Epimeletic (caregiving) behavior in cetaceans, In Whales, dolphins and Porpoises: International Symposium on Cetacean Research, K Norris, ed.; University of California Press: Berkeley, 1966, pp. 755-85.
64. Hart BL. Biological bases of the behavior of sick animals. Neuroscience and Biobehavioral Rev 1988; 12: 123-37.
65. Scott JP. The emotional basis of social behavior. Annals NY Academy Sci 1969; 159: 777-90.
66. Gilbert P. Evolutionary approaches to psychopathology: the role of natural defences. Australian & New Zealand J Psychiatry 2001; 35: 17-27.
67. Fabrega HJ. Disease and Social Behavior: An Interdisciplinary Perspective, MIT Press: Cambridge 1974.
68. Haskins R, et al. Minor illness and social behavior of infants and caregivers. J Applied Developmental Psychol 1981; 2: 117-28.
69. van Lawick-Goodall J. The behavior of free-living chimpanzees in the Gombe stream reserve. Animal Behavior Monographs 1968; 1
70. Parker G, Lipscombe P. The relevance of early parental experiences to adult dependency, hypochondriasis and utilization of primary physicians. Br J Medical Psychology 1980; 53: 355-63.
71. Kihlstrom JF, Cantor Kihlstrom L. Somatization as illness behavior. Advances in Mind-Body Medicine 2001; 17: 240-3.
72. Granek M. Hypochondriasis, acting out and counter-acting out. Br J Medical Psychology 1989; 62: 257-64.
73. Hofmann AD. The impact of illness in adolescence and coping behavior. Acta Paediatrica Scandinavica - Supplement 1975; 256: 29-33.
74. Henderson S. Care-eliciting behavior in man. J Nervous and Mental Disease 1974; 159: 172-81.
75. Bond MJ, Clark MS. A comparison of alternative indices of abnormal illness behavior derived from the Illness Behaviour Questionnaire. Psychology Health & Medicine 2002; 7: 203-13.
76. Bennett BK, Hickie IB, Vollmer-Conna US, et al. The relationship between fatigue, psychological and immunological variables in acute infectious illness. Australian & New Zealand J Psychiatry 1998; 32: 180-6.
77. Flegr J, Kodym P, Tolarova V. Correlation of duration of latent Toxoplasma gondii infection with personality changes in women. Biological Psychology 2000; 53: 57-68.
78. Katon W, Russo J, Ashley RL, Buchwald D. Infectious mononucleosis: psychological symptoms during acute and subacute phases of illness. General Hospital Psychiatry 1999; 21: 21-9.
79. Mullen L S, Blanco C, Vaughan SC, Vaughan R, Roose SP. Defense mechanisms and personality in depression. Depression & Anxiety 1999; 10: 168-74.
80. De Jonge P, Kempen GIJM, Sanderman R, et al. Depressive symptoms in elderly patients after a somatic illness event. Psychosomatics 2006; 47: 33-42.
81. de Beaurepaire R. Questions raised by the cytokine hypothesis of depression. Brain Behavior and Immunology 2002; 16: 610-7.
82. Yirmiya R, Pollack Y, Morag M, et al. Illness, cytokines, and depression. Annals of the New York Academy of Sciences 2000; 917: 478-87.
83. Vollmer-Conna U. Acute sickness behavior: an immune system-tobrain communication? Psychological Medicine 2001; 31: 761-7.
84. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Progress in Neuropsychopharmacology and Biologic Psychiatry 1995; 19: 11-38.
85. Capuron L, Miller AH. Cytokines and psychopathology: Lessons from Interferon-a. Biological Psychiatry 2004; 56: 819-908.
86. Maes M. Psychological stress, cytokines, and the inflammatory response system. Current Opinions in Psychiatry 1999; 12: 695-700.
87. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Molecular Psychiatry 2008; 13: 800-12.
88. Vaccarino V, Brennan M-L, Miller AH, et al. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biological Psychiatry 2008; 64: 476-83.
89. Seidel A, Rothermundt M, Rink L. Cytokine production in depressed patients, In Cytokines, Stress, and Depression, R Dantzer, EE Wollman, R Yirmiya, eds.; Kluwer Academic: New York, 1998, pp. 47-57.
90. Schwarz MJ, Chiang S, Muller N, Ackenheil M. T-Helper-1 and Thelper-2 responses in psychiatric disorders. Brain Behavior and Immunology 2001; 15: 340-70.
91. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: A meta-analytic review. Brain, Behavior, and Immunity 2001; 15: 199-226.
92. Li Y, Xiao B, Qiu W, et al. Altered expression of CD4(+)CD25(+) regulatory T cells and its 5-HT(1a) receptor in patients with major depression disorder. J Affective Disorders 2010; 124: 68-75.
93. Smith RS. The macrophage theory of depression. Medical Hypotheses 1991; 35: 298-306.
94. Leonard BE, Song C. Stress, depression, and the role of cytokines. Adv Exp Med Biol 1999; 461: 251-65.
95. Darko DF, Wilson NW, Gillion JC, Golshan S. A critical appraisal of mitogen induced lymphocyte proliferation in depressed patients. Am J Psychiatry 1991; 148: 337-44.
96. Seidel A, Arolt V, Hunstiger M, et al. Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatrica Scandanavia 1996; 94: 198-204.
97. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biological Psychiatry 2010; 67: 446-57.
98. Groer MW, Morgan M. Immune, health and endocrine characteristics of depressed postpartum mothers. Psychoneuroendocrinology 2007; 32: 133-9.
99. Mendlovic S, Mozes E, Eilat E, et al. Immune activation in nontreated suicidal major depression. Immunology Letters 1999; 67: 105-8.
100. Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain, Behavior, & Immunity 2011; 25: 335-9.
101. Irwin M, Daniels M, Smith TL, Bloom E, Weiner H. Impaired natural killer cell activity during bereavement. Brain, Behavior, & Immunity 1987; 1: 98-104.
102. Irwin M, Daniels M, Weiner H. Immune and neuroendocrine changes during bereavement. Psychiatric Clinics of North America 1987; 10: 449-65.
103. Maes M, Bosmans E, Suy E, et al. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1b and soluble interleukin-2 receptor production. Acta Psychiatrica Scandanavia 1991; 84: 379-86.
104. Seidel A, Arolt V, Hunstiger M, et al. Cytokine production and serum proteins in depression. Scandinavian J Immunology 1995; 41: 434-538.
105. Marques-Deak AH, Neto FL, Dominguez WV, et al. Cytokine profiles in women with different subtypes of major depressive disorder. J Psychiatric Res 2007; 51: 152-9.
106. Brambilla F, Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatrica Scandinavia 1998; 97: 309-13.
107. Steptoe A, Kunz-Ebrecht SR, Owen V. Lack of association between depressive symptoms and markers of immune and vascular inflammation in middle-aged men and women. Psychological Medicine 2003; 33: 667-74.
108. Stubner S, Schon T, Padberg F, et al. Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neuroscience Letters 1999; 259: 145-8.
109. Rief W, Pilger F, Ihle D, et al. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res 2001; 105: 165-74.
110. Reynaert C, Janne P, Jacques D, Tordeurs D, Zdanowicz N. Natural killer cell cytotoxity and course of illness in depressed mood. Psychiatria Danubina 2010; 22: S132-S4.
111. Brambilla F, Monteleone P, Maj M. Interleukin-1b and tumor necrosis factor-a in children with major depressive disorder or dysthymia. J Affective Disorders 2004; 78: 273-7.
112. Zaharia MD, Ravindran AV, Griffiths J, Merali Z, Anisman H. Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features. J Affective Disorders 2000; 58: 1-10.
113. Schlatter J, Ortuno F, Cervera-Enguix S. Monocytic parameters in patients with dysthymia versus major depression. J Affective Disorders 2004; 78: 243-7.
114. Anisman H, Ravindran AV, Griffiths J, Merali Z. Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biological Psychiatry 1999; 46: 1649-55.
115. Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999; 156: 837-41.
116. Panicker V, Evans J, Bjoro T, et al. A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clinical Endocrinology 2009; 71: 574-80.
117. Mendlewicz J. Disruption of the circadian timing systems: molecular mechanisms in mood disorders. CNS Drugs 2009; 23: 15-26.
118. Murphy-Eberenz K, Zandi PP, March D, et al. Is perinatal depression familial? J Affective Disorders 2006; 90: 49-55.
119. Bromberger JT, Schott LL, Kravitz HM, et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). Archives of General Psychiatry 2010; 67: 598-607.
120. Forster A, Young J. Specialist nurse support for patients with stroke in the community: a randomized controlled trial. Br Med J 1996; 312: 1642-6.
121. Narushima K, Kosier TJ, Robinson RG. Preventing poststroke depression: a 12-week double blind randomized treatment trial and 21-month follow-up. J Nervous Mental Disease 2002; 190: 296-303.
122. Rasmussen A, Lunde M, Poulsen DL, et al. A double-blind placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 2003; 44: 216-21.
123. Rothermundt M, Arolt V, Fenker J, et al. Different immune patterns in melancholic and non-melancholic major depression. European Archives Psychiatry Clinical Neurosci 2001; 251: 90-7.
124. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: A review of potential mechanisms. J Psychosomatic Res 2002; 53: 897-902.
125. Miller GE, Freedland KE, Carney RM. Depressive symptoms and the regulation of proinflammatory cytokine expression in patients with coronary heart disease. J Psychosomatic Res 2005; 59: 231-6.
126. Miller GE, Stetler DA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002; 90: 1279-83.
127. Lyness JM, Moynihan JA, Williford D, Cox C, Caine ED. Depression, medical illness, and interleukin-1beta in older cardiac patients. International J Psychiatry in Medicine 2001; 31: 305-10.
128. Pasic J, Levy WC, Sullivan MD. Cytokines in depression and heart failure. Psychosomatic Medicine 2003; 65: 181-93.
129. Allen-Mersh TG, Glover C, Cfordy C, Henderson DC, Davies M. Relation between depression and circulating immune products in patients with advanced colorectal cancer. J the Royal Soc Med 1998; 91: 408-13.
130. Jacobson CM, Rosenfeld B, Pessin H, Breitbart W. Depression and IL-6 blood plasma concentrations in advanced cancer patients. Psychosomatics 2008; 49: 64-6.
131. Jehn CF, Kuehnhardt D, Bartholomae A, et al. Biomarkers of depression in cancer patients. Cancer 2006; 107: 2723-9.
132. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001; 158: 1252-7.
133. Maier SF, Watkins LR. Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. Brain Behavior Immunol 2003; 17: S125-S31.
134. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Emotions, morbidity, and mortality: New perspectives from psychoneuroimmunology. Ann Rev Psychol 2002; 53: 83-107.
135. Kiecolt-Glaser JK, Glaser R. Depression and immune function: Central pathways to morbidity and mortality. J Psychosomatic Res 2002; 53: 873-6.
136. Kahl KG, Kruse N, Faller H, Weiss H, Rieckmann P. Expression of tumor necrosis factor-a and interferon-g mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002; 27: 671-81.
137. Nishio Y, Noguchi E, Ito S, et al. Mutation and association analysis of the interferon regulatory factor 2 gene (IRF2) with atopic dermatitis. J Human Genetics 2001; 46: 664-7.
138. Hashiro M, Okumura M. The relationship between the psychological and immunological state in patients with atopic dermatitis. J Dermatology Sci 1998; 16: 231-5.
139. Kalender B, Ozdemir AC, Koroglu G. Association of depression with markers of nutrition and inflammation in chronic kidney disease and end-staet renal disease. Nephron Clinical Practice 2006; 102: c115-c21.
140. Irwin M, Miller C. Decreased natural killer cell responses and altered interleukin-6 and interleukin-10 production in alcoholism:an interaction between alcohol dependence and African-American ethnicity. Alcoholism: Clinical Experimental Res 2000; 24: 560-9.
141. Redwine L, Dang J, Hall M, Irwin M. Disordered sleep, nocturnal cytokines, and immunity in alcoholics. Psychosomatic Medicine 2003; 65: 75-85.
142. Thomas AJ, Davis S, Morris C, et al. Increase in interleukin-1beta in late-life depression. Am J Psychiatry 2005; 162: 175-7.
143. Diniz BS, Teixeira AL, Talib L, Gattaz WF, Forlenza OV. Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients. Am J Geriatric Psychiatry 2010; 18: 172-6.
144. Hwang J-P, Tsai S-J, Hong C-J, et al. Interleukin-1 beta -511C/T genetic polymorphism is associated with age of onset of geriatric depression. NeuroMolecular Med 2009; 11: 322-7.
145. McAdams C, Leonard BE. Neutrophil and monocyte phagocytosis in depressed patients. Progress Neuro-Psychopharmacology Biological Psychiatry 1993; 17: 971-84.
146. Frommberger UH, Bauer J, Haselbauer P, et al. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. European Archives of Psychiatry Clinical Neurosci 1997; 247: 228-33.
147. van den Biggelaar AHJ, Gussekloo J, de Craen AJM, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Experimental Gerontol 2007; 42: 693-701.
148. Forti P, Rietti E, Pisacane N, et al. Blood inflammatory proteins and risk of incident depression in the elderly. Dementia Geriatric Cognitive Disorders 2010; 29: 11-20.
149. Capitanio JP, Mendoza SP, Cole SW. Nervous temperament in infant monkeys is associated with reduced sensitivity of leukocytes to cortisol's influence on trafficking. Brain, Behavior, Immunity 2011; 25: 151-9.
150. O'Donovan A, Hughes BM, Slavich GM, et al. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotionbiology relationships. Brain, Behavior, Immunity 2010; 24: 1074-7.
151. Koo JW, Russo SJ, Ferguson D, Nestler NJ, Duman RS. Nuclear factor-kb is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Nat Acad Sci USA 2010; 107: 2669-74.
152. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry & Neuroscience 2009; 34: 4-20.
153. Anisman H, Merali Z. Cytokines, stress, and depressive illness. Brain Behavior Immunol 2002; 16: 513-24.
154. Anisman H, Merali Z, Hayley S. Sensitization associated with stressors and cytokine treatments. Brain, Behavior, Immunity 2003; 17: 86-93.
155. Silverman MN, Macdougall MG, Hu F, et al. Endogenous glucocorticoids protect against TNF-alpha-induced increases in anxietylike behavior in virally infected mice. Molecular Psychiatry 2007; 12: 408-17.
156. Miller GE, Cohen S, Ritchey AK. Chronic Psychological Stress and the Regulation of Pro-Inflammatory Cytokines: A Glucocorticoid-Resistance Model. Brain, Behavior, & Immunity 2002; 21: 531-41.
157. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biological Psychiatry 2001; 49: 391-404.
158. Pace TW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006; 163: 1630-3.
159. Miller GE, Rohleder N, Stetler C, Kirschbaum C. Clinical depression and regulation of the inflammatory response during acute stress. Psychosomatic Medicine 2005; 67: 679-87.
160. Chen P, Jiang T, Ouyang J, Cui Y, Chen Y. Epigenetic programming of diverse glucocorticoid response and inflammatory/ immune-mediated disease. Medical Hypotheses 2009; 73: 657-8.
161. De Gucht V, Fischler B, Demanet C. Immune dysfunction associated with chronic professional stress in nurses. Psychiatry Res 1999; 85: 105-11.
162. Owen N, Poulton T, Hay FC, Mohamed-Ali V, Steptoe A. Socioeconomic status, C-reactive protein, immune factors, and responses to acute mental stress. Brain, Behavior, & Immunity 2003; 17: 286-95.
163. Irwin M. Effects of sleep and sleep loss on immunity and cytokines. Brain Behavior and Immunology 2002; 16: 503-12.
164. Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory markers and sleep disturbance in major depression. Psychosomatic Medicine 2005; 67: 187-94.
165. Savard J, Laroche L, Simard S, Ivers H, Morin CM. Chronic insomnia and immune functioning. Psychosomatic Medicine 2003; 65: 211-21.
166. Danielson AM, Matheson K, Anisman H. Cytokine levels at a single time point following a reminder stimulus among women in abusive dating relationships: Relationship to emotional states. Psychoneuroendocrinology 2011; 36: 40-50.
167. Capuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection of interferonalpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 160: 1342-5.
168. Dunn AJ. Cytokine activation of the HPA axis. Ann NY Academy Sci 2000; 917: 608-17.
169. Tilders FJH, Schmidt ED. Cross-sensitization between immune and non-immune stressors. A role in the etiology of depression? Advances Exp Med Biol 1999; 461: 179-97.
170. Piser TM. Linking the cytokine and neurocircuitry hypotheses of depression: a translational framework for discovery and development of novel anti-depressants. Brain, Behavior, Immunity 2010; 24: 515-24.
171. Neveu PJ, Castanon N. Is there evidence for an effect of antidepressant drugs on immune function. Adv Exp Med Biol 1999; 461: 267-81.
172. Himmerich H, Milenovic S, Fulda S, et al. Regulatory T cells increased while IL-1beta decreased during antidepressant therapy. J Psychiatric Res 2010; 44: 1052-7.
173. Janssen DGA, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Human Psychopharmacol 2010; 25: 201-15.
174. Xia F, DePierre JW, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta, and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacol 1996; 34: 27-37.
175. Maes M, Song C, Lin AH, et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999; 20: 370-9.
176. Hashioka S, Klegeris A, Monji A, et al. Antidepressants inhibit interferon-y-induced microglial production of IL-6 and nitric oxide. Experimental Neurology 2007; 206: 33-42.
177. Szuster-Ciesielska A, Tustanowska-Stachura A, Slotwinska M, Marmurowska-Michalowska H, Kanderfer-Szerszen M. In vitro immunoregulatory effects of antidepressants in healthy volunteers. Polish J Pharmacol 2003; 55: 353-62.
178. Horikawa H, Kato TA, Mizoguchi Y, et al. Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Progress in Neuro-Psychopharmacol Biological Psychiatry 2010; 34: 1306-16.
179. Obuchowicz E, Kowlaski J, Labuzek K, et al. Amitryptyline and nortryptyline inhibit interleukin-1b and tumor necrosis factor-a release by rat mixed glial microglial cell cultures. International J Neuropsychopharmacol 2006; 9: 27-35.
180. Yirmiya R, Pollak Y, Baak O, et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacol 2001; 24: 531-44.
181. Suzuki E, Shintani F, Kanba S, Asai M, Nakaki T. Induction of interleukin-1b and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci Letters 1996; 215: 201-4.
182. Sluzewska A, Rybakowski JK, Laciak M, et al. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Annals of NY Acadamy of Sci 1995; 762: 474-6.
183. Basterzi AD, Aydemir C, Kisa C, et al. Il-6 levels decrease with SSRI treatment in patients with major depression. Human Psychopharmacol 2005; 20: 473-6.
184. Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacol 2000; 23: 13-9.
185. Kagaya A, Kugaya A, Takebayashi M, et al. Plasma concentrations of interleukin-1 beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 2001; 43: 59-62.
186. Tulner DM, Smith OR, Schins A, et al. Antidepressive effect of mirtazapine in post-myocardial infarction depression is associated with soluble TNF-R1 increase: data from the MIND-IT. Neuropsychobiol 2011; 63: 169-76.
187. Himmerich H, Milenovic S, Fulda S, et al. Regulatory T cells increased while IL-1beta decreased during antidepressant therapy. J Psychiatric Res 2010; 44: 1052-7.
188. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatric Res 2007; 41: 326-31.
189. Lanquillon S, Krieg J-C, Bening-Abu-Shach U, Vedder H. Cytokine productionand treatment response in major depressive disorder. Neuropsychopharmacol 2000; 22: 370-9.
190. Maes M, Bosmans E, De Jongh R, et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853-8.
191. Chou R, Clark EC, Helfand M. Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventive Services Task Force. Annals Internal Med 2004; 140: 465-79.
192. Williams I. Epidemiology of hepatitis C in the United States. Am J Medicine 1999; 107: 2S-9S.
193. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention, MMWR Recomm Rep 1998; 47: 1-39.
194. Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose inteferon alpha treatment. Psychopharmacology 2001; 152: 383-9.
195. Capuron L, Pagnoni G, Demetrashvili M, et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biological Psychiatry 2005; 58: 190-6.
196. Tanaka H, Maeshima S, Shigekawa Y, et al. Neuropsychological impairment and decreased regional cerebral blood flow by interferon treatment in patients with chronic hepatitis: a preliminary study. Clinical Exp Med 2006; 6: 124-8.
197. Pomova NI, Ivanikov IO, Siutkin VE. Use of peg-intron in combined treatment of chronic liver disease caused by HIV infection. Eksperimental'Naia i Klinicheskaia Gastroenterologiia 2003; 1: 42-5.
198. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. General Hospital Psychiatry 2003; 25: 34-8.
199. Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Digestive Diseases Sci 2002; 20: 284-8.
200. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000; 157: 867-76.
201. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribarin therapy: prevalence and prediction. J Clinical Psychiatry 2005; 66: 41-8.
202. Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ. Treatment of cytokine-induced depression. Brain Behavior and Immunology 2002; 16: 575-80.
203. Donnelly S. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. Oncological Nursing Forum 1998; 25: 921-7.
204. Malaguarnera M, Di Fazio I, Restuccia S, et al. Interferon alphainduced depression in chronic hepatitis C patients: Comparison between different types of interferon alpha. Neuropsychobiology 1998; 37: 93-7.
205. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clinical Oncol 2000; 18: 2316-26.
206. Pavol MA, Meyers CA, Rexer JL, et al. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurol 1995; 45: 947-50.
207. Lotrich FE. Risk factors and prevention of interferon-induced depression. Dialogues in Clinical Neuroscience 2009; 11: 417-26.
208. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Australia 2000; 173: 359-61.
209. Gleason OC, Yates WR. Five cases of interferon-a-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40: 510-2.
210. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clinical Psychiatry 2002; 63: 194-8.
211. Kraus MR, Schafer A, Schottker K, et al. Therapy of interferoninduced depression in chronic hepatitis C with citalopram: a randomized, double-blind, placebo-controlled study. Gut 2008; 57: 531-6.
212. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. New England J Medicine 2001; 344: 961-6.
213. Goldman LS. Successful treatment of interferon-a-induced mood disorder with nortriptyline. Psychosomatics 1994; 35: 412-3.
214. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-a. Am J Gastroenterology 1993; 88: 760-1.
215. Hauser P, Soler R, Reed S, et al. Prophylactic treatment of depression induced by interferon-a. Psychosomatics 2000; 41: 439-42.
216. Farah A. Interferon-induced depression treated with citalopram. J Clinical Psychiatry 2002; 63: 166-7.
217. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry 2002; 7: 942-7.
218. Morasco BJ, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-a-induced depression in patients with hepatitis C. J Affective Disorders 2007; 103: 83-90.
219. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003; 25: 34-8.
220. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942-7.
221. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-a in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol 2002; 26: 643-52.
222. Prather AA, Rabinovitz M, Pollock BG, Lotrich FE. Cytokineinduced depression during IFN-_ treatment: the role of IL-6 and sleep quality. Brain, Behavior, & Immunity 2009; 23: 1109-16.
223. Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-a and ribavirin treatment. Molecular Psychiatry 2008; 14: 1095-104.
224. Lotrich FE, Ferrell RF, Rabinovitz M, Pollock BG. Labile anger during interferon-alpha treatment is associated with a polymorphism in tumor necrosis factor-alpha. Clinical Neuropharmacology 2010; in press.
225. Kraus MR, Al-Taie O, Schefer A, et al. Serotonin-1A receptor gene (HTR1A) vairation predicts interferon-induced depression chronic hepatitis C. Gastroenterology 2007; 132: 1279-86.
226. Gochee PA, Powell EE, Purdie DM, et al. Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. Psychosomatics 2004; 45: 49-57.
227. Yoshida K, Alagbe O, Wang X, et al. Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferoninduced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 2005; 52: 55-61.
228. Lotrich FE. Management of Psychiatric Disease in Hepatitis C Treatment Candidates. Current Hepatitis Reports 2011; 9: 113-8.
229. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Archives of General Psychiatry 2001; 58: 445-52.
230. Strike PC, Wardle J, Steptoe A. Mild acute inflammatory stimulation induces transient negative mood. J Psychosomatic Res 2004; 57: 189-94.
231. Brydon L, Walker C, Wawrzyniak A, et al. Syndergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. look up
232. Makino M, Kitano Y, Hirohashi M, Takasuna K. Enhancement of immobility in mouse forced swimming test by treatment with human interferon. European J Pharmacology 1998; 356: 1-7.
233. Makino M, Kitano Y, Komiyama C, Hirohashi M, Takasuna K. Involvement of central opioid systems in human interferon-a induced immobility in the mouse forced swimming test. Br J Pharmacol 2000; 130: 1269-74.
234. Makino M, Kitano Y, Komiyama C, Takasuna K. Human interferon-a increases immobility in the forced swimming test in rats. Psychopharmacology 2000; 148: 106-10.
235. Yamano M, Yuki H, Yasuda S, Miyata K. Corticotropin-releasing hormone1 receptors mediate consensus interferon-a YM643-induced depression-like behavior in mice. J Pharmacol Experimental Therapeutics 2000; 292: 181-7.
236. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon-a administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997; 747: 348-51.
237. Dunn AL, Crnic LS. Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. Brain, Behavior, & Immunity 1993; 7: 104-11.
238. Anisman H, Kokkinidis L, Merali Z. Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes. Brain Behavior and Immunology 2002; 16: 544-56.
239. Fahey B, Hickey B, Kelleher D, O'Dwyer AM, O'Mara SM. The widely-used anti-viral drug interferon-alpha induces depressiveand anxiogenic-like effects in healthy rats. Behavioural Brain Res 2007; 182: 80-7.
240. De La Garza R, Asnis GM, Pedrosa E, et al. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendorcine activation in rats. Progress in Neuro-Psychopharmacology Biological Psychiatry 2005; 9: 781-92.
241. Larson SJ, Dunn AJ. Behavioral effects of cytokines. Brain, Behavior, and Immunity 2001; 15: 371-87.
242. Dantzer R, Aubert A, Bluthe R-M, et al. Mechanisms of the behavioral effects of cytokines. Adv Exp Med Biol 1999; 461: 83-106.
243. Dantzer R, Kelley KW. Twenty years of research on cytokineinduced sickness behavior. Brain, Behavior, Immunity 2007; 21: 153-60.
244. Maier SF, Nguyen KT, Deak T, Milligan ED, Watkins LR. Stress, learned helplessness, and brain interleukin-1b. Adv Exp Med Biol 1999; 461: 235-50.
245. Bluthe R-M, Castanon N, Pousset F, et al. Central injection of IL-10 antagonizes the behavioural effects of lipopolysaccharide in rats. Psychoneuroendocrinology 1999; 24: 301-11.
246. Parnet P, Kelley KW, Bluthe R-M, Dantzer R. Expression and regulation of interleukin-1 receptors in the brain. Role in cytokniesinduced sickness behavior. J Neuroimmunology 2002; 125: 5-14.
247. Zubareva OE, Krasnova IN, Abdurasulova IN, et al. Effects of serotonin synthesis blockade on interleukin-1b action in the brain of rats. Brain Res 2001; 915: 244-7.
248. Lacosta S, Merali Z, Anisman H. Influence of interleukin-1b on exploratory behaviors, plasma ACTH, corticosterone, and central biogenic amines in mice. Psychopharmacology 1998; 137: 351-61.
249. Lacosta S, Merali Z, Anisman H. Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation 2000; 8: 83-90.
250. Bluthe R-M, Dantzer R, Kelley KW. Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor a in mice. European J Pharmacology 1991; 209: 281-3.
251. Bluthe R-M, Dantzer R, Kelly KW. Central mediation of the effects of interleukin-1 on social exploration and body weight in mice. Psychoneuroendocrinology 1997; 22: 1-11.
252. Connor TJ, Song C, Leonard BE, Merali Z, Anisman H. An assessment of the effects of central interleukin-1b, -2, -6, and tumor necrosis factor-a administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience 1998; 84: 923-33.
253. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 1999; 461: 199-234.
254. Bret-Diban JL, Bluthe RM, Kent S, Kelley KW, Dantzer R. Lipopolysaccharide and interleukin-1 depress food-motivated behavior in mice by a vagal-mediated mechanism. Brain Behavior and Immunology 1995; 9: 242-6.
255. Anisman H, Kokkinidis L, Borowski T, Merali Z. Differential effects of IL-1, IL-2, and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res 1998; 779: 177-87.
256. Merali Z, Brennan K, Brau P, Anisman H. Dissociating anorexia and anhedonia elicited by interleukin-1b: antidepressant and gender effects on respondnig for free chow and earned sucrose intake. Psychopharmacology 2002; 165: 413-8.
257. Kustova Y, Sei Y, Morse HC, Basile AS. The influence of a targeted deletion of the IFNg gene on emotional behaviors. Brain, Behavior, and Immunity 1998; 12: 308-24.
258. Schrott LM, Crnic LS. Attenuation of behavioral abnormalities in autoimmune mice by chronic soluble interferon-g receptor treatment. Brain Behavior and Immunol 1998; 12: 90-106.
259. Goshen I, Yirmiya R. The role of pro-inflammatory cytokines in memory processes and neural plasticity, In Psychoneuroimmunology, 4E, R Ader, DL Felton, N Cohen, eds.; Elsevier, Inc., 2007.
260. Goshen I, Yirmiya R. Interleukin-1 (IL-1): A central regulator of stress responses. Frontiers in Neuroendocrinol 2009; 30: 30-45.
261. Sato T, Suzuki E, Yokoyama M, et al. Chronic intraperitoneal injection of interferon-alpha reduces serotonin levels in various regions of rat brain, but does not change levels of serotonin transporter mRNA, nitrite or nitrate. Psychiatry Clinical Neurosci 2006; 60: 499-506.
262. Maes M, Scharpe S, Meltzer HY, et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994; 54: 143-60.
263. Capuron L, Schroecksnadel S, Feart C, et al. Chronic low-grade inflammation in elderly person is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biological Psychiatry 2011; xx: xx.
264. Wang J, Dunn AJ. Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem Int 1998; 33: 143-54.
265. Zhang J-J, Terreni L, De Simoni MG, Dunn AJ. Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. Neurochem Int 2001; 38: 303-8.
266. Clement HW, Buschmann J, Rex S, et al. Effects of interferongamma, interleukin-1 beta, and tumor necrosis factor-alpha on the serotonin metabolism in the nucleus raphe dorsalis of the rat. J Neural Transmission 1997; 104: 981-91.
267. Hayley S, Wall P, Anisman H. Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor-a: peripheral and central mechanisms. Eur J Neurosci 2002; 15: 1061-76.
268. Abe S, Hori T, Suzuki T, et al. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochemical Res 1999; 24: 359-63.
269. Ramamoorty S, Ramamoorty JD, Prasad PD, et al. Regulation of the human serotonin transporter by interleukin-1 beta. Biochemical Biophysical Res Communications 1995; 216: 560-7.
270. Mossner R, Heils A, Stober G, et al. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 1998; 33: 251-4.
271. Morikawa O, Sakai N, Obara H, Saito N. Effects of interferonalpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998; 349: 317-24.
272. Tsao C-W, Lin Y-S, Cheng J-T, et al. Interferon-alpha-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter. J Psychopharmacol 2008; 22: 753-60.
273. Ling ZD, Potter ED, Lipton JW, Carvey PM. Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp Neurol 1998; 149: 411-23.
274. Song C. The interaction between cytokines and neurotransmitters in depression and stress: possible mechanism of antidepressant treatments. Human Psychopharmacol 2000; 15: 199-211.
275. Song C, Merali Z, Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interfleukin-1, interleukin-2, or interleukin-6 treatment. Neuroscience 1999; 88: 823-36.
276. Petitto JM, McCarthy DB, Rinker CM, Huang Z, Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J Neuroimmunol 1997; 73: 183-90.
277. Capuron L, Pagnoni G, Demetrashvili MF, et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacol 2007; 32: 2384-92.
278. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237-49.
279. Hayley S, Poulter M, Merali Z, Anisman H. The pathogenesis of clinical depression: stressor-and cytokine-induced alterations of neuroplasticity. Neuroscience 2005; 135: 659-78.
280. Mehler MF, Kessler JA. Hematolymphopoietic and inflammatory cytokines in neural development. Trends in Neuroscis 1997; 20: 357-65.
281. Zhao B, Schwartz JP. Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives. J Neurosci Res 1998; 52: 7-16.
282. Kaneko N, Kudo K, Mabuchi T, et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacol 2006; 31: 2619-26.
283. Pace TWW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain, Behavior, Immunity 2007; 21: 9-19.
284. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negatiev beta isoform, a mechanism for the generation of glucocorticoid resistance. PNAS 2001; 98: 6865-70.
285. Johnson JD, O'Connor KA, Deak T, et al. Prior stressor exposure sensitizes LPS-induced cytokine production. Brain Behavior Immunol 2002; 16: 461-76.
286. Curran B, O'Connor JJ. The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. Neuroscience 2001; 108: 83-90.
287. Coogan A, O'Neill LAJ, CO'Connor JJ. The p38 MAP kinase inhibitor SB203580 antagonises the inhibitory effect of interleukin-1b on long-term potentiation in the rat dentate gyrus in vitro. Neuroscience 1999; 93: 57-69.
288. Krueger JM. The role of cytokines in sleep regulation. Curr Pharm Des 2008; 14: 3408-16.
289. Krueger JM, Dinarello CA, Shoham S, et al. Interferon alpha-2 enhances slow-wave sleep in rabbits. Int J Immunopharmacol 1987; 9: 23-30.
290. Krueger JM, Fang J, Floyd RA. Relationships between sleep and immune function, In Regulation of sleep and circadian rhythms, FW Turek, PC Zee, eds.; Marcel Dekker, Inc.: New York, 1999.
291. Krueger JM, Majde JA. Cytokines and sleep. Int Archives Allergy Immunol 1995; 106: 97-100.
292. Kubota T, Brown RA, Fang J, Krueger JM. Interleukin-15 and interleukin-2 enhance non-REM sleep in rabbits. Am J Physiol Regulatory Integrative Comparative Physiol 2001; 281: R1004-R12.
293. Opp MR, Smith EM, Hughes Jr TK. Interleukin-10 (cytokine synthesis inhibitory factor) acts in the central nervous system of rats to reduce sleep. J Neuroimmunol 1995; 60: 165-8.
294. Pollmacher T, Haack M, Schuld A, Reichenberg A, Yirmiya R. Low levels of circulating inflammatory cytokines--Do they affect human brain functions? Brain Behavior Immunol 2002; 16: 525-32.
295. Roscoe JA, Morrow GR, Hickok JT, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002; 10: 329-36.
296. Koyanagi S, Ohdo S. Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism. Molecular Pharmacol 2002; 62: 1393-9.
297. Kunugi H, Hori H, Adachi N, Numakawa T. Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clinical Neurosci 2010; 64: 477-59.
298. Chourbaji S, Brandwein C, Gass P. Altering BDNF expression by genetics and/or environment: impact for emotional and depressionlike behaviour in laboratory mice. Neurosci Biobehavioral Rev 2011; 35: 599-611.
299. Carvalho AL, Caldeira MV, Santos SD, Duarte CB. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 2008; 153: S310-S24.
300. Ninan I, Bath KG, Dagar K, et al. The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. J Neurosci 2010; 30: 8866-70.
301. Aydemir C, Yalcin ES, Aksaray S, et al. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Progress in Neuropsychopharmacology and Biological Psychiatry 2006; 30: 1256-60.
302. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clinical Neurosci 2010; 64: 341-57.
303. Bocchio-Chiavetto L, Zanardini R, Bortolomasi M, et al. Electroconvulsive therapy (ECT) increases serum brain derived neurotrophic factor (BDNF) in drug resistant depressed patients. European Neuropsychopharmacol 2006; 16: 620-4.
304. Gervasoni N, Aubry JM, Bondolfi G, et al. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005; 51: 234-8.
305. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biological Psychiatry 2008; 64: 527-32.
306. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biological Psychiatry 2003; 54: 70-5.
307. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biological Psychiatry 2001; 50: 260-5.
308. Castren E, Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Developmental Neurobiol 2010; 70: 289-97.
309. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacol 1998; 37: 1553-61.
310. Verhagen M, van der Meij A, van Deurzen P, et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 2010; 15: 260-71.
311. Cirulli F, Reif A, Herterich S, et al. A novel BDNF polymorphism affects plasma protein levels in interaction with early adversity in rhesus macaques. Psychoneuroendocrinology 2011; 36: 382-79.
312. Ozan E, Okur H, Eker C, et al. The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. Brain Res Bulletin 2010; 81: 61-5.
313. Duncan LE, Hutchison KE, Carey G, Craighead WE. Variation in brain-derived neurotrophic factor (BDNF) gene is associated with symptoms of depression. J Affective Disorders 2009; 115: 215-9.
314. Zhou Z, Lu T, Xu G, et al. Decreased serum brain-derived neurotrophic factor (BDNF) is associated with post-stroke depression but not with BDNF gene Val66Met polymorphism. Clinical Chem Lab Med 2011; 49: 185-9.
315. Terracciano A, Martin B, Ansari D, et al. Plasma BDNF concentration, Val66Met genetic variant and depression-related personality traits. Genes, Brain, Behavior 2010; 9: 512-218.
316. Pregelj P, Nedic G, Paska AV, et al. The association between brain-derived neurotrophic factor polymorphism (BDNF Val66Met) and suicide. J Affective Disorders 2011; 128: 287-90.
317. Sarchiapone M, Carli V, Roy A, et al. Association of polymorphism (Val66Met) of brain-derived neurotrophic factor with suicide attempts in depressed patients. Neuropsychobiology 2008; 57: 139-45.
318. Kanellopoulos D, Gunning FM, Morimoto SS, et al. Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatric Psychiatry 2011; 19: 13-22.
319. Borroni B, Grassi M, Archetti S, et al. BDNF genetic variations increase the risk of Alzheimer's disease-related depression. J Alzheimer's Disease 2009; 18: 867-75.
320. Lavebratt C, Aberg E, Sjoholm LK, Forsell Y. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J Affective Disorders 2010; 125: 249-55.
321. Kim JM, Stewart R, Kim SW, et al. BDNF genotype potentially modifying the association between incident stroke and depression. Neurobiol Aging 2008; 29: 789-92.
322. Gatt JM, Kuan SA, Dobson-Stone C, et al. Association between BDNF Val66Met polymorphism and trait depression is mediated via resting EEG alpha band activity. Biological Psychol 2008; 79: 275-84.
323. Hayden EP, Klein DN, Dougherty LR, et al. The role of brainderived neurotrophic factor genotype, parental depression, and relationship discord in predicting early-emerging negative emotionality. Psychological Sci 2010; 21: 1678-85.
324. Aguilera M, Arias B, Wichers M, et al. Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychological Med 2009; 39: 1425-32.
325. Montag C, Basten U, Stelzel C, Fiebach CJ, Reuter M. The BDNF Val66Met polymorphism and anxiety: support for animal knock-in studies from a genetic association study in humans. Psychiatry Res 2010; 179: 86-90.
326. Jiang X, Xu K, Hoberman J, et al. BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacol 2005; 30: 1353-61.
327. Beevers CG, Wells TT, McGeary JE. The BDNF Val66Met polymorphism is associated with rumination in healthy adults. Emotion 2009; 9: 579-84.
328. Gatt JM, Williams LM, Schofield PR, et al. Impact of the HTR3A gene with early life trauma on emotional brain networks and depressed mood. Depression Anxiety 2010; 27: 752-9.
329. Gatt JM, Nemeroff CB, Dobson-Stone C, et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Molecular Psychiatry 2009; 14: 681-95.
330. Lau JY, Goldman D, Buzas B, et al. BDNF gene polymorphism (Val66Met) predicts amygdala and anterior hippocampus responses to emotional faces in anxious and depressed adolescents. Neuroimage 2010; 53: 952-61.
331. Taylor WD, Zuchner S, McQuoid DR, et al. Social support in older individuals: the role of the BDNF Val66Met polymorphism. Am J Medical Genetics. Part B, Neuropsychiatric Genetics 2008; 147B: 1205-12.
332. Schule C, Zill P, Baghai TC, et al. Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients. Psychoneuroendocrinol 2006; 31: 1019-25.
333. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Archives of General Psychiatry 2009; 66: 488-97.
334. Schumacher J, Jamra RA, Becker T, et al. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biological Psychiatry 2005; 58: 307-14.
335. Middeldorp CM, Slof-Op't Landt MC, Medland SE, et al. Anxiety and depression in children and adults: influence of serotonergic and neurotrophic genes? Genes, Brain, Behavior 2010; 9: 808-16.
336. Figueira P, Malloy-Diniz L, Campos SB, et al. An association study between the Val66Met polymorphism of the BDNF gene and postpartum depression. Archives of Women's Mental Health 2010; 13: 285-9.
337. Chen L, Lawlor DA, Lewis SJ, et al. Genetic association study of BDNF in depression: finding from two cohort studies and a metaanalysis. Am J Medical Genetics. Part B, Neuropsychiatric Genetics 2008; 147B: 814-21.
338. Wray NR, James MR, Handoko HY, et al. Association study of candidate variants from brain-derived neurotrophic factor and dystrobrevin-binding protein 1 with neuroticism, anxiety, and depression. Psychiatric Genetics 2008; 18: 219-25.
339. Suchanek R, Owczarek A, Kowalczyk M, Kucia K, Kowalski J. Association between C-281A and val66met functional polymorphisms of BDNF gene and risk of recurrent major depressive disorder in Polish population. J Molecular Neuroscience 2011; 43: 524-30.
340. Ribeiro L, Busnello JV, Cantor RM, et al. The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. Neuroreport 2007; 18: 1291-3.
341. Goodyer IM, Croudace T, Dudbridge F, Ban M, Herbert J. Polymorphisms in BDNF (Val66Met) and 5-HTTLPR, morning cortisol and subsequent depression in at-risk adolescents. Br J Psychiatry 2010; 197: 365-71.
342. Kim SJ, Cho SJ, Jang HM, et al. Interaction between brain-derived neurotrophic factor Val66Met polymorphism and recent negative stressor in harm avoidance. Neuropsychobiology 2010; 61: 19-26.
343. Frodl T, Schule C, Schmitt G, et al. Association of the brainderived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Archives General Psychiatry 2007; 64: 410-6.
344. Montag C, Weber B, Fliessbach K, Elger C, Reuter M. The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression. Psychological Med 2009; 39: 1831-9.
345. Joffe RT, Gatt JM, Kemp AH, et al. Brain derived neurotrophic factor Val66Met polymorphism, the five factor model of personality and hippocampal volume: Implications for depressive illness. Human Brain Mapping 2009; 30: 1246-56.
346. Benjamin S, McQuoid DR, Potter GG, et al. The brain-derived neurotrophic factor Val66Met polymorphism, hippocampal volume, and cognitive function in geriatric depression. Am J Geriatric Psychiatry 2010; 18: 323-31.
347. Gonul AS, Kitis O, Eker MC, et al. Association of the brainderived neurotrophic factor Val66Met polymorphism with hippocampus volumes in drug-free depressed patients. World J Biological Psychiatry 2011; 12: 110-8.
348. Montag C, Reuter M, Newport B, Elger C, Weber B. The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: evidence from a genetic imaging study. Neuroimage 2008; 42: 1554-9.
349. Chi MH, Chang HH, Lee SY, et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J Affective Disorders 2010; 126: 430-5.
350. Rajewska-Rager A, Skibinska M, Szczepankiewicz A, et al. Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression. Psychiatria Polska 2008; 42: 915-23.
351. Zou YF, Wang Y, Liu P, et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology 2010; 61: 71-8.
352. Mata J, Thompson RJ, Gotlib IH. BDNF genotype moderates the relation between physical activity and depressive symptoms. Health Psychology 2010; 29: 130-3.
353. Bocchio-Chiavetto L, Miniussi C, Zanardini R, et al. 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neuroscience Letters 2008; 437: 130-4.
354. Cortese GP, Barrientos RM, Maier SF, Patterson SL. Aging and a peripheral immune challenge interact to reduce mature brainderived neurotrophic factor and activation of TrkB, PLCgamma1, and ERK in hippocampal synaptoneurosomes. J Neurosci 2011; 31: 4274-9.
355. Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW. Interleukin-1 beta impairs brain derived neurotrophic factorinduced signal transduction. Neurobiol Aging 2008; 29: 1380-93.
356. Barrientos RM, Sprunger DB, Campeau S, et al. Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neurosci 2003; 121: 847-53.
357. Guan Z, Fang J. Peripheral immune activation by lipopolysaccharide decreases neurotrophins in the cortex and hippocampus in rats. Brain Behavior Immunity 2006; 20: 64-71.
358. Bercik P, Verdu EF, Foster JA, et al. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology 2010; 139: 2102-12.
359. Kenis G, Prickaerts J, Os J, et al. Depressive symptoms following interferon-alpha therapy: mediated by immune-induced reductions in brain derived neurotrophic facotr? International J Neuropsychopharmacol 2011
360. Rezaee F, Rellick SL, Piedimonte G, et al. Neurotrophins regulate bone marrow stromal cell IL-6 expression through the MAPK pathway. PLoS ONE 2010; 5: e9690.
361. Kimata H. Brain-derived neurotrophic factor selectively enhances allergen-specific IgE production. Neuropeptides 2005; 39: 379-83.
362. Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuro 865-70.
363. Besser M, Wank R. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 1999; 162: 6303-6.
364. Nakahashi T, Fujimura H, Altar CA, et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Letters 2000; 470: 113-7.
365. Kunz D, Walker G, Bedoucha M, et al. Expression profiling and Ingenuity biological function analyses of interleukin-6-versus nerve growth factor-stimulated PC12 cells. BMC Genomics 2009; 10: 90.
366. Furuno T, Nakanishi M. Neurotrophic factors increase tumor necrosis factor-alpha-induced nuclear translocation of NF-kappaB in rat PC12 cells. Neurosci Letters 2006; 392: 240-4.
367. Prakash YS, Thompson MA, Pabelick CM. Brain-derived neurotrophic factor in TNF-alpha modulation of Ca2+ in human airway smooth muscle. Am J Respiratory Cell & Molecular Biology 2009; 41: 603-11.
368. Liguori M, Fera F, Patitucci A, et al. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis. Brain Res 2009; 1256: 123-8.
369. Norman GJ, Karelina K, Zhang N, et al. Stress and IL-1beta contribute to the development of depressive-like behavior following peripheral nerve injury. Molecular Psychiatry 2010; 15: 404-14.
370. Beck RDJ, King MA, Ha GK, et al. IL-2 deficiency results in altered septal and hippocampal cytoarchitecture: relation to development and neurotrophins. J Neuroimmunol 2005; 160: 146-53.
371. Lisak RP, Benjamins J, Bealmear B, et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J Neuroinflammation 2007; 4: 30.
372. Numakawa T, Suzuki S, Kumamaru E, et al. BDNF function and intracellular signaling in neurons. Histology Histopathol 2010; 25: 237-58.
373. Felger JC, Alagbe O, Pace TWW, et al. Early activation of p38 mitogen activated protein kinase is associated with interferonalpha-induced depression and fatigue. 2011
374. Duman CH, Schlesinger L, Kodama M, Russel DS, Duman RS. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biological Psychiatry 2007; 61: 661-70.
375. Kairisalo M, Korhonen L, Sepp M, et al. NF-kappaB-dependent regulation of brain-derived neurotrophic factor in hippocampal neurons by X-linked inhibitor of apoptosis protein. Eur J Neurosci 2009; 30: 958-66.
376. Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Annals of Rheumatologic Diseases 2002; 61: 960-76.
377. Carter JD, Valeriano J, Vasey FB. Crohn disease worsened by Anakinra administration. J Clinical Rheumatol 2003; 9: 276-7.
378. Jonville-Bera AP, Guilmot J-L, Aspe G, Autret-Leca E, Magnant J. Is exogenous administration of IL-1ra (anakinra) likely to induce severe depression? Eur J Clinical Pharmacol 2010; 67: 213-4.
379. Rose-John S. Cytokines as therapeutic drugs. J Interferon and Cytokine Res 2002; 22: 505-16.
380. Asadullah K, Docke WD, Sabat R, Volk HD, Sterry W. The treatment of psoriasis with IL-10: rationale and review of the first clinical trials. Expert Opinion on Investigational Drugs 2000; 9: 95-102.
381. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebocontrolled trial. Am J Respiratory Critical Care Med 1999; 160: 1816-23.
382. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy and Clinical Immunol 2001; 107: 963-70.
383. Tyring S, Gottleib A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebocontrolled randomised phase III trial. Lancet 2006; 367: 29-35.
384. Krishnan R, Cella D, Leonardi C, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007; 157: 1275-7.
385. Beyer CE, Dwyer JM, Piesla MJ, et al. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Disease 2010; 39: 148-55.
386. Moreira FA, Crippa JA. The psychiatric side-effects of rimonabant. Revista Brasileira de Psiquiatria 2009; 31: 145-53.
387. Hill MN, Gorzalka BB. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS & Neurological Disorders Drug Targets 2009; 8: 451-8.
388. Maes M, Christophe A, Bosmans E, Lin A-H, Neels H. In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress. Biological Psychiatry 2000; 47: 910-20.
389. Rondanelli M, Giacosa A, Opizzi A, et al. Effect of omega-3 fatty acids supplementation on depressive symptoms and on healthrelated quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J the American College of Nutrition 2010; 29: 55-64.
390. Rondanelli M, Giacosa A, Opizzi A, et al. Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life. J Nutrition, Health & Aging 2011; 15: 37-44.
391. Lu DY, Tsao YY, Leung YM, Su KP. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids. Neuropsychopharmacol 2010; 35: 2238-48.
392. Wojcicki JM, Heyman MB. Maternal omega-3 fatty acid supplementation and risk for perinatal maternal depression. J Maternal-Fetal Neonatal Med 2011; 24: 680-6.
393. Ketterer MW, Brymer J, Rhoads K, Kraft P, Lovalla WR. Is aspirin, as used for antithrombosis, an emotion-modulating agent? J Psychosomatic Res 1996; 40: 53-8.
394. Akhondzadeh S, Jafari S, Faisi F. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depression Anxiety 2009; 26: 607-11.
395. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry 2006; 11: 680-4.
396. Karimi K, Inman MD, Bienenstock J, Forsythe P. Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respiratory and Critical Care Med 2009; 179: 186-93.
397. Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alphinduced interleukin-8 expression. Infection Immunity 2004; 72: 5308-14.
398. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nature Reviews Gastroenterology and Hepatol 2009; 6: 306-14.
399. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. PNAS early edition 2011; pnas.1102999108
400. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Archives Of Neurology 2010; 67: 1442-8.
401. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6: 797-801.
402. Pae CU, Marks DM, Han C, Patkar AA. Does minocycline have an antidepressant effect? Biomedical Pharmacotherapy 2008; 62: 308-11.
403. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Progress in Neuro-Psychopharmacol Biological Psychiatry 2008; 32: 380-6.
404. Prasad AS. Impact of the discovery of human zinc deficiency on health. J the American College of Nutrition 2009; 28: 257-65.
405. Dybala M, Maciag D, Cichy A, et al. Medium supplementation with zinc enables detection of imipramine-induced adaptation in glycine/NMDA receptors labeled with [3H]L-689,560. Source Pharmacological Reports 2006; 58: 753-7.
406. Roy A, Evers SE, Avison WR, Campbell MK. Higher zinc intake buffers the impact of stress on depressive symptoms in pregnancy. Nutrition Res 2010; 30: 695-704.
407. Yi LT, Li CF, Zhan X, et al. Involvement of monoaminergic system in the antidepressant-like effect of the flavonoid naringenin in mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010; 34: 1223-8.
408. Yamanaka K-I, Yuta A, Kakeda M, et al. SLIT improves cedar pollinosis by restoring IL-10 production from Tr1 and Monocytes IL-10 productivity is critical for becoming allergic. Allergology International 2011; 60: 45-51.
409. Shatry A, Chirinos J, Gorin MA, Jones M, Levy RB. Targeting Treg cells in situ: emerging expansion strategies for (CD4(+) CD25(+)) regulatory T cells. Biology of Blood Marrow Transplantation 2009; 15: 1239-43.
410. Tsukada H, Ochi H, Maekawa T, et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterol 2009; 136: 1796-805.
411. Anderson DR, Meyers MJ, Vernier WF, et al. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem 2007; 50: 2647-54.
412. Buckley GM, Fosbeary R, Fraser JL, et al. IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines. Bioorganic Med Chem Letters 2008; 18: 3656-60.
413. Dumaz N, Marais R. Integrating signals between cAMP and RAS/RAF/MEK/ERK singaling pathways. FEBS J 2005; 272: 3491-504.
414. Yoshii A, Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Developmental Neurobiol 2010; 70: 304-22.
415. Cohen P. Targeting protein kinases for the development of antiinflammatory drugs. Curr Opinion Cell Biol 2009; 21: 317-24.
416. Lotrich FE, El-Gabalawy H, Guenther L, Ware C. The role of inflammation in the pathophysiology of depression: different treatments and their effects. J Rheumatol 2011; 88: 48-54.